Inactive Instrument
Elite Pharmaceuticals Inc Stock OTC Bulletin Board
Stocks
US28659T2006
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| 08-14 | Elite Pharmaceuticals, Inc., Q1 2027 Earnings Call, Aug 14, 2026 | |
| 08-14 | Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
| Market Cap | 257M 227M 215M 194M 365M 24.68B 370M 2.57B 989M 12.62B 967M 946M 40.46B | P/E 2025 |
-108x | P/E 2026 | 12x |
|---|---|---|---|---|---|
| Enterprise Value | 233M 206M 195M 176M 331M 22.38B 336M 2.33B 897M 11.44B 877M 857M 36.69B | EV / Sales 2025 |
5.52x | EV / Sales 2026 | 2.44x |
| Free-Float |
77.61% | Yield 2025 * |
-
| Yield 2026 | - |
Last Transcript: Elite Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Dick
CEO | Chief Executive Officer | 71 | 23/10/2009 |
Nasrat Hakim
CEO | Chief Executive Officer | 65 | 02/08/2013 |
Carter Ward
DFI | Director of Finance/CFO | 62 | 01/07/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Barry Dash
BRD | Director/Board Member | 95 | 01/04/2005 |
Jeffrey Whitnell
BRD | Director/Board Member | 70 | 23/10/2009 |
Nasrat Hakim
CHM | Chairman | 65 | 13/01/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.33% | +0.53% | +51.65% | +114.95% | 1,056B | |
| -1.06% | -1.65% | +42.78% | +70.63% | 645B | |
| -0.65% | -1.32% | +12.98% | +76.45% | 465B | |
| -2.66% | -1.87% | +73.13% | +41.70% | 368B | |
| -0.06% | -4.12% | +36.31% | +39.39% | 335B | |
| -0.79% | +3.01% | +21.11% | +27.79% | 275B | |
| -1.19% | -3.09% | +10.75% | +10.61% | 255B | |
| -0.50% | +3.80% | +49.37% | +58.28% | 229B | |
| -1.47% | -1.53% | +34.28% | +101.15% | 188B | |
| Average | -0.87% | +0.12% | +36.93% | +60.11% | 423.98B | |
| Weighted average by Cap. | -0.86% | +0.30% | +40.24% | +71.74% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 84.04M 74.01M 70.12M 63.3M 119M 8.06B 121M 839M 323M 4.12B 316M 309M 13.21B | 149M 131M 124M 112M 211M 14.27B 214M 1.49B 572M 7.3B 559M 547M 23.4B |
| Net income | -4.31M -3.8M -3.6M -3.25M -6.13M -414M -6.2M -43.07M -16.57M -211M -16.2M -15.85M -678M | 44.87M 39.51M 37.44M 33.8M 63.7M 4.3B 64.53M 448M 172M 2.2B 168M 165M 7.05B |
| Net Debt | -400K -353K -334K -302K -569K -38.4M -576K -4M -1.54M -19.63M -1.5M -1.47M -62.94M | -23.98M -21.12M -20.01M -18.06M -34.05M -2.3B -34.49M -239M -92.13M -1.18B -90.05M -88.09M -3.77B |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
